BALTIMORE, Md., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued research coverage of Lorus Therapeutics, Inc. (TSX:LOR) (OTCPK:LRUSF), a discovery, research and clinical development stage company with a focus on novel cancer drugs.
Lorus' strategy is based on drug discovery and early – mid stage development, followed by out-license of products to pharmaceutical partners that could each approach hundreds of millions of dollars in value. Lorus has multiple first-in-class products based on two separate platforms, including LOR-253, which is a unique and potentially blockbuster Phase I clinical trial stage proprietary drug that suppresses tumor growth and IL-17E, which is a powerful immunotherapy.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"With a diversified, active portfolio based upon 29 issued patents and 19 pending, Lorus' strength in discovery and development could result in a virtually endless pipeline of products. Genentech, a subsidiary of drug giant Roche Group, entered into a license agreement with Lorus regarding IL-17E, which is a huge positive for Lorus. The agreement demonstrates confidence in the vast potential of the immunotherapy and commercial value to Lorus. In our view, LOR is significantly undervalued relative to its peers, the value of its products, and future out-licensing and partnership potential."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Lorus Therapeutics, Inc. (TSX:LOR) (OTCPK:LRUSF): Lorus is a biopharmaceutical company focused on the discovery, research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. The Company also has expertise in antimicrobial drug discovery. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR and in the U.S. it is listed under the symbol LRUSF. For more information, visit the Company's website at http://www.lorusthera.com.
CONTACT: Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 email@example.comSource:Goldman Small Cap Research